Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $4,000,000.00 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the completion of the sale, the senior vice president owned 1,274 shares of the company’s stock, valued at approximately $127,400. The trade was a 96.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jolanda Howe also recently made the following trade(s):

• On Monday, August 3rd, Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $105.29, for a total transaction of $193,733.60.
• On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00.
• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total transaction of $264,458.30.

Mirum Pharmaceuticals Stock Down 0.8%

Shares of NASDAQ MIRM opened at $96.31 on Friday. Mirum Pharmaceuticals, Inc. has a 52-week low of $63.23 and a 52-week high of $130.00. The firm has a fifty day moving average of $111.20 and a 200-day moving average of $101.94. The stock has a market capitalization of $6.25 billion, a PE ratio of -6.62 and a beta of 0.52. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The firm had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. During the same quarter in the previous year, the company earned ($0.12) earnings per share. The company’s quarterly revenue was up 37.9% on a year-over-year basis. On average, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on MIRM. Morgan Stanley set a $137.00 price objective on Mirum Pharmaceuticals in a report on Thursday, August 6th. CLSA set a $146.00 target price on Mirum Pharmaceuticals in a report on Monday, June 15th. Citizens Jmp dropped their target price on shares of Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating for the company in a research report on Thursday, August 6th. Wolfe Research began coverage on shares of Mirum Pharmaceuticals in a report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target on the stock. Finally, Evercore reaffirmed an “outperform” rating and set a $138.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $137.33.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. ABS Investment Management LLC purchased a new stake in shares of Mirum Pharmaceuticals in the second quarter worth about $245,847,000. Quantbot Technologies LP acquired a new stake in shares of Mirum Pharmaceuticals in the second quarter valued at about $44,000. Cullen Frost Bankers Inc. acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $30,000. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $32,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $32,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.